Brokerages forecast that Spero Therapeutics Inc (NASDAQ:SPRO) will report ($1.04) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Spero Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.23) and the highest estimate coming in at ($0.92). Spero Therapeutics reported earnings of ($0.60) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 73.3%. The business is expected to issue its next earnings report on Thursday, March 12th.
On average, analysts expect that Spero Therapeutics will report full year earnings of ($3.11) per share for the current fiscal year, with EPS estimates ranging from ($3.34) to ($2.94). For the next year, analysts expect that the company will post earnings of ($3.65) per share, with EPS estimates ranging from ($5.27) to ($3.01). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Spero Therapeutics.
Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings results on Monday, November 4th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.10). The firm had revenue of $4.64 million for the quarter, compared to analysts’ expectations of $2.03 million. Spero Therapeutics had a negative return on equity of 43.10% and a negative net margin of 287.11%.
Hedge funds have recently modified their holdings of the stock. Acadian Asset Management LLC acquired a new position in Spero Therapeutics during the second quarter worth $25,000. Marshall Wace LLP acquired a new position in Spero Therapeutics during the first quarter worth $39,000. D.A. Davidson & CO. acquired a new position in Spero Therapeutics during the second quarter worth $115,000. Stifel Financial Corp acquired a new position in Spero Therapeutics during the third quarter worth $137,000. Finally, Wells Fargo & Company MN raised its holdings in Spero Therapeutics by 187.9% during the second quarter. Wells Fargo & Company MN now owns 13,660 shares of the company’s stock worth $157,000 after purchasing an additional 8,915 shares during the last quarter. 48.36% of the stock is owned by hedge funds and other institutional investors.
NASDAQ:SPRO traded up $0.17 during mid-day trading on Friday, reaching $11.09. 59,684 shares of the stock were exchanged, compared to its average volume of 48,266. The company has a 50 day simple moving average of $10.99 and a 200-day simple moving average of $10.85. The stock has a market capitalization of $210.60 million, a P/E ratio of -4.27 and a beta of 2.10. The company has a quick ratio of 6.90, a current ratio of 6.90 and a debt-to-equity ratio of 0.04. Spero Therapeutics has a 1 year low of $5.52 and a 1 year high of $14.48.
Spero Therapeutics Company Profile
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.
Featured Story: What are the qualifications of a portfolio manager?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.